November 23, 2016 - By Peter Erickson
In a public form that’s submitted to the U.S. Security and Exchange Commission, it was exposed that the SVP & General Counsel of Momenta Pharmaceuticals Inc Bruce Leicher, an insider in bear’s eye, made a deal for 1,030 shares of the stock exchange listed company, having an approx. value of $14,069 USD using the average stock value of $13.7 USD. Now, he owns a total of 182,576 shares or 0.26% of the company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).
Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 24.89% above today’s ($13.7) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Maxim Group downgraded it to “Sell” rating and $6 target price in Wednesday, September 7 report. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Neutral” rating given on Thursday, August 6 by Goldman Sachs. The stock has “Overweight” rating given by Barclays Capital on Tuesday, October 11. The stock has “Hold” rating given by Maxim Group on Friday, January 8. On Monday, June 6 the stock rating was initiated by Goldman Sachs with “Neutral”. JP Morgan initiated it with “Overweight” rating and $26 target price in Friday, November 13 report. Leerink Swann maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Wednesday, May 4 with “Outperform” rating. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Hold” rating by Aegis Capital on Tuesday, November 22. The stock has “Equal-Weight” rating given by Barclays Capital on Monday, November 23. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, October 13.
Insitutional Activity: The institutional sentiment decreased to 1.35 in 2016 Q2. Its down 0.03, from 1.38 in 2016Q1. The ratio dived, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Amica Retiree Medical owns 11,264 shares or 0.1% of their US portfolio. Blackrock has 90,261 shares for 0% of their US portfolio. Commerzbank Aktiengesellschaft Fi, a Germany-based fund reported 44,859 shares. Quantitative Systematic Strategies Ltd Llc has invested 0.08% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Blackrock Grp holds 0% or 83,031 shares in its portfolio. Capstone Asset owns 18,183 shares or 0.01% of their US portfolio. Citigroup holds 10,041 shares or 0% of its portfolio. The South Dakota-based South Dakota Inv Council has invested 0.04% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Cornerstone Advsr accumulated 1,263 shares or 0.01% of the stock. Creative Planning accumulated 1,600 shares or 0% of the stock. New York State Common Retirement Fund accumulated 256,437 shares or 0% of the stock. D E Shaw & Communication accumulated 0.03% or 1.75 million shares. Bogle Mgmt Ltd Partnership De has 11,268 shares for 0.01% of their US portfolio. Susquehanna Llp has 14,001 shares for 0% of their US portfolio. Moreover, California State Teachers Retirement has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 136,276 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 6 insider sales for $188,231 net activity. Another trade for 1,030 shares valued at $12,415 was made by Leicher Bruce on Friday, August 19. Roach James M. sold $13,151 worth of stock or 1,091 shares. The insider Shapiro Bennett M sold 5,200 shares worth $67,600. $70,704 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by WHEELER CRAIG A. Another trade for 1,049 shares valued at $12,644 was made by Kaundinya Ganesh Venkataraman on Friday, August 19. On Friday, August 19 Shea Richard P sold $11,717 worth of the stock or 972 shares.
About 121,719 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 37.98% since April 21, 2016 and is uptrending. It has outperformed by 32.65% the S&P500.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $907.68 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It currently has negative earnings. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 EPS, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.